Continental Controls has announced a Rs 50 crore Rights Issue to fund its transition toward a tech-driven retail and pharmacy ecosystem. The company reported a net loss of Rs 1.27 lakh for FY 2025-26 as it pivots its business model. Investors should track the regulatory clearance of the fundraising and the successful integration of its newly acquired brand rights.
Continental Controls Targets Rs 50 Crore Fundraise
Continental Controls has announced a Rs 50 crore Rights Issue to support its transition to a technology-driven retail platform.
Reader Takeaway: The company is pivoting to an asset-light model, though FY26 financials show a shift to a net loss.
What just happened
The Board of Directors approved a Rights Issue of up to Rs 50 crore to eligible shareholders, with the Draft Letter of Offer now filed with the BSE. Concurrently, the company is shifting away from advisory services toward a tech-heavy retail pharmacy and general shopping model. It has secured commercial usage rights for 'Ready Shopping' and 'Ready Pharmacy' from Onelife Capital Advisors Limited for Rs 53.99 lakh plus royalties.
Why this matters
The fundraising signals a clear shift in the company's capital allocation, with proceeds earmarked for technology infrastructure and working capital. The strategic move aims to leverage the newly acquired brand rights to build a tech-ecosystem. However, the company reported a net loss of Rs 1.27 lakh for FY 2025-26, compared to a profit of Rs 6.89 lakh in the previous year, highlighting the financial strain of this transformation.
The backstory
On January 30, 2026, the company faced a ransomware attack that corrupted certain electronic records. Management stated that financial data for the fiscal year was reconstructed using best-effort records, and internal security controls have since been reinforced to prevent recurrence.
Governance changes
To support the new direction, the company has appointed Dr. Ranu Jain and Mr. Santosh Bhattacharjee as Non-Executive Independent Directors. Additionally, Ms. Anushree Tekriwal has joined as the new Company Secretary and Compliance Officer.
Risks to watch
Investors should monitor the execution of the technology platform rollout, as the company is currently loss-making. The dependency on the success of the Rights Issue for working capital remains a key risk factor alongside the integration of the acquired pharmacy and retail brands.
What to track next
Watch for the final approval of the Rights Issue by regulatory bodies and updates on the deployment of capital into the planned technology infrastructure.